Skip to main content

Advertisement

Articles

Page 6 of 17

  1. Truncated mis-disordered tau protein plays an important role in the pathogenesis of Alzheimer’s disease (AD) and frontotemporal dementia (FTD). Tau294–305, an epitope in the truncated tau, is essential for pathol...

    Authors: Mei Ji, Xi-xiu Xie, Dong-qun Liu, Xiao-lin Yu, Yue Zhang, Ling-Xiao Zhang, Shao-wei Wang, Ya-ru Huang and Rui-tian Liu

    Citation: Alzheimer's Research & Therapy 2018 10:55

    Content type: Research

    Published on:

  2. Alzheimer’s disease (AD) is characterized by physiologically endogenous proteins amyloid beta (Aβ) and tau undergoing a conformational change and accumulating as soluble oligomers and insoluble aggregates. Tau...

    Authors: Krystal Herline, Frances Prelli, Pankaj Mehta, Claire MacMurray, Fernando Goñi and Thomas Wisniewski

    Citation: Alzheimer's Research & Therapy 2018 10:54

    Content type: Research

    Published on:

  4. Synaptic and axonal loss are two major mechanisms underlying Alzheimer’s disease (AD) pathogenesis, and biomarkers reflecting changes in these cellular processes are needed for early diagnosis and monitoring t...

    Authors: Madhurima Chatterjee, Marta Del Campo, Tjado H. J. Morrema, Matthijs de Waal, Wiesje M. van der Flier, Jeroen J. M. Hoozemans and Charlotte E. Teunissen

    Citation: Alzheimer's Research & Therapy 2018 10:52

    Content type: Research

    Published on:

  5. Drugs for dementia have been available in England since 1997. Since their launch, there have been several changes to national guidelines and initiatives that may have influenced prescribing. These include chan...

    Authors: Venexia M. Walker, Neil M. Davies, Patrick G. Kehoe and Richard M. Martin

    Citation: Alzheimer's Research & Therapy 2018 10:51

    Content type: Research

    Published on:

  6. We investigated the effects of lifetime cumulative ginseng intake on cognitive function in a community-dwelling population-based prospective cohort of Korean elders.

    Authors: Silvia Kyungjin Lho, Tae Hui Kim, Kyung Phil Kwak, Kayoung Kim, Bong Jo Kim, Shin Gyeom Kim, Jeong Lan Kim, Tae Hyun Kim, Seok Woo Moon, Jae Young Park, Joon Hyuk Park, Seonjeong Byun, Seung Wan Suh, Ji Young Seo, Yoonseop So, Seung-Ho Ryu…

    Citation: Alzheimer's Research & Therapy 2018 10:50

    Content type: Research

    Published on:

  7. Amyloid-β (Aβ) immunotherapy is one of the most promising disease-modifying strategies for Alzheimer’s disease (AD). Despite recent progress targeting aggregated forms of Aβ, low antibody brain penetrance rema...

    Authors: Stina Syvänen, Greta Hultqvist, Tobias Gustavsson, Astrid Gumucio, Hanna Laudon, Linda Söderberg, Martin Ingelsson, Lars Lannfelt and Dag Sehlin

    Citation: Alzheimer's Research & Therapy 2018 10:49

    Content type: Research

    Published on:

  8. The ε4 allele of the apolipoprotein E gene (APOE-ε4) is the strongest genetic factor for late-onset Alzheimer’s disease. During middle age, cognitively healthy APOE-ε4 carriers already show several brain alterati...

    Authors: Grégory Operto, Raffaele Cacciaglia, Oriol Grau-Rivera, Carles Falcon, Anna Brugulat-Serrat, Pablo Ródenas, Rubén Ramos, Sebastián Morán, Manel Esteller, Nuria Bargalló, José Luis Molinuevo and Juan Domingo Gispert

    Citation: Alzheimer's Research & Therapy 2018 10:48

    Content type: Research

    Published on:

  9. The contribution of psychological factors to brain health and resilience remains poorly investigated. Furthermore, their possible interaction with ‘classical’ cognitive reserve (CR) estimates in predicting per...

    Authors: David Bartrés-Faz, Gabriele Cattaneo, Javier Solana, Josep M. Tormos and Alvaro Pascual-Leone

    Citation: Alzheimer's Research & Therapy 2018 10:47

    Content type: Research

    Published on:

  10. In patients with frontotemporal dementia, it has been shown that brain atrophy occurs earliest in the anterior cingulate, insula and frontal lobes. We used visual rating scales to investigate whether identifyi...

    Authors: Giorgio G. Fumagalli, Paola Basilico, Andrea Arighi, Martina Bocchetta, Katrina M. Dick, David M. Cash, Sophie Harding, Matteo Mercurio, Chiara Fenoglio, Anna M. Pietroboni, Laura Ghezzi, John van Swieten, Barbara Borroni, Alexandre de Mendonça, Mario Masellis, Maria C. Tartaglia…

    Citation: Alzheimer's Research & Therapy 2018 10:46

    Content type: Research

    Published on:

  11. The range of onset ages within some PSEN1 families is wide, and a few cases of reduced penetrance of PSEN1 mutations have been reported. However, published data on reduced penetrance have been limited to clinical...

    Authors: Steinunn Thordardottir, Elena Rodriguez-Vieitez, Ove Almkvist, Daniel Ferreira, Laure Saint-Aubert, Anne Kinhult-Ståhlbom, Håkan Thonberg, Michael Schöll, Eric Westman, Anders Wall, Maria Eriksdotter, Henrik Zetterberg, Kaj Blennow, Agneta Nordberg and Caroline Graff

    Citation: Alzheimer's Research & Therapy 2018 10:45

    Content type: Research

    Published on:

  12. The study investigated whether donepezil exerts symptomatic benefit in patients with posterior cortical atrophy (PCA), an atypical variant of Alzheimer’s disease.

    Authors: Basil H. Ridha, Sebastian Crutch, Dawn Cutler, Christopher Frost, William Knight, Suzie Barker, Norah Epie, Elizabeth K. Warrington, Riitta Kukkastenvehmas, Jane Douglas and Martin N. Rossor

    Citation: Alzheimer's Research & Therapy 2018 10:44

    Content type: Research

    Published on:

  13. Vitamin D deficiency is associated with an increased risk of Alzheimer’s disease and increased beta-amyloid (Aβ) in animals. Hence we sought to investigate the relationship between plasma 25-hydroxyvitamin D (...

    Authors: Fati Nourhashemi, Claudie Hooper, Christelle Cantet, Catherine Féart, Isabelle Gennero, Pierre Payoux, Anne Sophie Salabert, Sophie Guyonnet, Philipe De Souto Barreto and Bruno Vellas

    Citation: Alzheimer's Research & Therapy 2018 10:43

    Content type: Research

    Published on:

  14. Mild cognitive impairment (MCI) is a heterogeneous syndrome resulting from Alzheimer’s disease (AD) as well as to non-AD and non-neurodegenerative conditions. A subset of patients with amnestic MCI (aMCI) pres...

    Authors: Chiara Cerami, Alessandra Dodich, Sandro Iannaccone, Giuseppe Magnani, Roberto Santangelo, Luca Presotto, Alessandra Marcone, Luigi Gianolli, Stefano F. Cappa and Daniela Perani

    Citation: Alzheimer's Research & Therapy 2018 10:42

    Content type: Research

    Published on:

  15. With upcoming therapeutic interventions for patients with primary progressive aphasia (PPA), instruments for the follow-up of patients are needed to describe disease progression and to evaluate potential thera...

    Authors: Elisa Semler, Sarah Anderl-Straub, Ingo Uttner, Janine Diehl-Schmid, Adrian Danek, Beate Einsiedler, Klaus Fassbender, Klaus Fliessbach, Hans-Jürgen Huppertz, Holger Jahn, Johannes Kornhuber, Bernhard Landwehrmeyer, Martin Lauer, Rainer Muche, Johannes Prudlo, Anja Schneider…

    Citation: Alzheimer's Research & Therapy 2018 10:41

    Content type: Research

    Published on:

  16. Alzheimer’s disease (AD) is a devastating neurodegenerative disorder bearing multiple pathological hallmarks suggestive of complex cellular/molecular interplay during pathogenesis. Transgenic mice and nonhuman...

    Authors: Feng-Qin Zhou, Juan Jiang, Chelsea M. Griffith, Peter R. Patrylo, Huaibin Cai, Yaping Chu and Xiao-Xin Yan

    Citation: Alzheimer's Research & Therapy 2018 10:40

    Content type: Research

    Published on:

  17. Down syndrome (DS) may be considered a genetic form of Alzheimer’s disease (AD) due to universal development of AD neuropathology, but diagnosis and treatment trials are hampered by a lack of reliable blood bi...

    Authors: Andre Strydom, Amanda Heslegrave, Carla M. Startin, Kin Y. Mok, John Hardy, Jurgen Groet, Dean Nizetic and Henrik Zetterberg

    Citation: Alzheimer's Research & Therapy 2018 10:39

    Content type: Research

    Published on:

  18. Symptomatic benefits have been reported for 5-HT6 receptor antagonists in Alzheimer’s disease (AD) trials. SAM-760 is a potent and selective 5-HT6 receptor antagonist that has demonstrated central 5-HT6 receptor ...

    Authors: Terence Fullerton, Brendon Binneman, William David, Marielle Delnomdedieu, James Kupiec, Peter Lockwood, Jessica Mancuso, Jeffrey Miceli and Joanne Bell

    Citation: Alzheimer's Research & Therapy 2018 10:38

    Content type: Research

    Published on:

  20. Comparison of disease progression between placebo-group patients from randomised controlled trials (RCTs) and real-world patients can aid in assessing the generalisability of RCT outcomes. This analysis compar...

    Authors: Catherine Reed, Mark Belger, Grazia Dell’Agnello, Kristin Kahle-Wrobleski, Gopalan Sethuraman, Ann Hake, Joel Raskin and David Henley

    Citation: Alzheimer's Research & Therapy 2018 10:36

    Content type: Research

    Published on:

  21. We explored the presence of both reserve and resilience in late-converter mild cognitive impairment due to Alzheimer’s disease (MCI-AD) and in patients with slowly progressing amyloid-positive MCI by assessing...

    Authors: Matteo Bauckneht, Andrea Chincarini, Roberta Piva, Dario Arnaldi, Nicola Girtler, Federico Massa, Matteo Pardini, Matteo Grazzini, Hulya Efeturk, Marco Pagani, Gianmario Sambuceti, Flavio Nobili and Silvia Morbelli

    Citation: Alzheimer's Research & Therapy 2018 10:35

    Content type: Research

    Published on:

  23. Cerebrospinal fluid (CSF) biomarkers have been used to increase the evidence of underlying Alzheimer’s disease (AD) pathology in mild cognitive impairment (MCI). However, CSF biomarker-based classification oft...

    Authors: Inês Baldeiras, Isabel Santana, Maria João Leitão, Helena Gens, Rui Pascoal, Miguel Tábuas-Pereira, José Beato-Coelho, Diana Duro, Maria Rosário Almeida and Catarina Resende Oliveira

    Citation: Alzheimer's Research & Therapy 2018 10:33

    Content type: Research

    Published on:

  24. Cerebrospinal fluid (CSF) biomarkers are increasingly being used to support a diagnosis of Alzheimer’s disease (AD). Their clinical utility for differentiating AD from non-AD neurodegenerative dementias, such ...

    Authors: Ross W. Paterson, Catherine F. Slattery, Teresa Poole, Jennifer M. Nicholas, Nadia K. Magdalinou, Jamie Toombs, Miles D. Chapman, Michael P. Lunn, Amanda J. Heslegrave, Martha S Foiani, Philip S. J. Weston, Ashvini Keshavan, Jonathan D. Rohrer, Martin N. Rossor, Jason D. Warren, Catherine J. Mummery…

    Citation: Alzheimer's Research & Therapy 2018 10:32

    Content type: Research

    Published on:

  25. We explored the diagnostic performance of cerebrospinal fluid (CSF) biomarkers in allowing differentiation between frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease (AD), as well as between FTLD...

    Authors: Joery Goossens, Maria Bjerke, Sara Van Mossevelde, Tobi Van den Bossche, Johan Goeman, Bart De Vil, Anne Sieben, Jean-Jacques Martin, Patrick Cras, Peter Paul De Deyn, Christine Van Broeckhoven, Julie van der Zee and Sebastiaan Engelborghs

    Citation: Alzheimer's Research & Therapy 2018 10:31

    Content type: Research

    Published on:

  26. Body fluid biomarkers have great potential for different clinical purposes, including diagnosis, prognosis, patient stratification and treatment effect monitoring. This is exemplified by current use of several...

    Authors: Charlotte E. Teunissen, Markus Otto, Sebastiaan Engelborghs, Sanna-Kaisa Herukka, Sylvain Lehmann, Piotr Lewczuk, Alberto Lleó, Armand Perret-Liaudet, Hayrettin Tumani, Martin R. Turner, Marcel M. Verbeek, Jens Wiltfang, Henrik Zetterberg, Lucilla Parnetti and Kaj Blennow

    Citation: Alzheimer's Research & Therapy 2018 10:30

    Content type: Review

    Published on:

  27. Substantial evidence indicates that the relationship between blood pressure (BP) measures and cognitive functioning is inconsistent, complex, and age-related. Pulse pressure (PP), which can not only reflect ar...

    Authors: Tingting Sha, Wenwei Cheng and Yan Yan

    Citation: Alzheimer's Research & Therapy 2018 10:29

    Content type: Research

    Published on:

  28. Recent evidence derived from functional magnetic resonance imaging (fMRI) studies suggests that functional hubs (i.e., highly connected brain regions) are important for mental health. We found recently that gl...

    Authors: Nicolai Franzmeier, Julia Hartmann, Alexander N. W. Taylor, Miguel Á. Araque-Caballero, Lee Simon-Vermot, Lana Kambeitz-Ilankovic, Katharina Bürger, Cihan Catak, Daniel Janowitz, Claudia Müller, Birgit Ertl-Wagner, Robert Stahl, Martin Dichgans, Marco Duering and Michael Ewers

    Citation: Alzheimer's Research & Therapy 2018 10:28

    Content type: Research

    Published on:

  29. Dementia due to Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) are the two most common neurodegenerative causes of dementia. They commonly occur together, especially in older people, but clinical...

    Authors: Alan J. Thomas, Fariba Mahin-Babaei, Mohammad Saidi, Debbie Lett, John Paul Taylor, Lauren Walker and Johannes Attems

    Citation: Alzheimer's Research & Therapy 2018 10:27

    Content type: Research

    Published on:

  30. The underlying mechanism of brain glucose hypometabolism, an invariant neurodegenerative feature that tightly correlates with cognitive impairment and disease progression of Alzheimer’s disease (AD), remains e...

    Authors: Shaoming Sang, Xiaoli Pan, Zhichun Chen, Fan Zeng, Shumei Pan, Huimin Liu, Lirong Jin, Guoqiang Fei, Changpeng Wang, Shuhua Ren, Fangyang Jiao, Weiqi Bao, Weiyan Zhou, Yihui Guan, Yiqiu Zhang, Hongcheng Shi…

    Citation: Alzheimer's Research & Therapy 2018 10:26

    Content type: Research

    Published on:

  31. Neuroinflammation has gained increasing attention as a potential contributing factor in Alzheimer’s disease (AD) pathology. A clinical cerebrospinal fluid biomarker capable of monitoring this process during th...

    Authors: Frederic Brosseron, Andreas Traschütz, Catherine N. Widmann, Markus P. Kummer, Pawel Tacik, Francesco Santarelli, Frank Jessen and Michael T. Heneka

    Citation: Alzheimer's Research & Therapy 2018 10:25

    Content type: Research

    Published on:

  32. The phosphodiesterase (PDE) 7 inhibitor S14 is a cell-permeable small heterocyclic molecule that is able to cross the blood–brain barrier. We previously found that intraperitoneal treatment with S14 exerted ne...

    Authors: Fernando Bartolome, Macarena de la Cueva, Consuelo Pascual, Desiree Antequera, Tamara Fernandez, Carmen Gil, Ana Martinez and Eva Carro

    Citation: Alzheimer's Research & Therapy 2018 10:24

    Content type: Research

    Published on:

  33. Survival after dementia diagnosis varies considerably. Previous studies were focused mainly on factors related to demographics and comorbidity rather than on Alzheimer’s disease (AD)-related determinants. We s...

    Authors: Hanneke F. M. Rhodius-Meester, Hilkka Liedes, Ted Koene, Afina W. Lemstra, Charlotte E. Teunissen, Frederik Barkhof, Philip Scheltens, Mark van Gils, Jyrki Lötjönen and Wiesje M. van der Flier

    Citation: Alzheimer's Research & Therapy 2018 10:23

    Content type: Research

    Published on:

  34. Simultaneous consideration of two neuropathological traits related to Alzheimer’s disease (AD) has not been attempted in a genome-wide association study.

    Authors: Jaeyoon Chung, Xiaoling Zhang, Mariet Allen, Xue Wang, Yiyi Ma, Gary Beecham, Thomas J. Montine, Steven G. Younkin, Dennis W. Dickson, Todd E. Golde, Nathan D. Price, Nilüfer Ertekin-Taner, Kathryn L. Lunetta, Jesse Mez, Richard Mayeux, Jonathan L. Haines…

    Citation: Alzheimer's Research & Therapy 2018 10:22

    Content type: Research

    Published on:

  35. A growing number of pharmacological and nonpharmacological trials have been performed to test the efficacy of approved or experimental treatments in Alzheimer disease (AD) and mild cognitive impairment (MCI). ...

    Authors: Elisa Canu, Elisabetta Sarasso, Massimo Filippi and Federica Agosta

    Citation: Alzheimer's Research & Therapy 2018 10:21

    Content type: Review

    Published on:

  36. The prevalence of dementia with Lewy bodies (DLB) and dementia in Parkinson’s disease (PDD) in routine clinical practice is unclear. Prevalence rates observed in clinical and population-based cohorts and neuro...

    Authors: Joseph P. M. Kane, Ajenthan Surendranathan, Allison Bentley, Sally A. H. Barker, John-Paul Taylor, Alan J. Thomas, Louise M. Allan, Richard J. McNally, Peter W. James, Ian G. McKeith, David J. Burn and John T. O’Brien

    Citation: Alzheimer's Research & Therapy 2018 10:19

    Content type: Research

    Published on:

  37. Current approved drugs for Alzheimer’s disease (AD) only attenuate symptoms, but do not cure the disease. The pirinixic acid derivate MH84 has been characterized as a dual gamma-secretase/proliferator activate...

    Authors: Maximilian Pohland, Maren Pellowska, Heike Asseburg, Stephanie Hagl, Martina Reutzel, Aljoscha Joppe, Dirk Berressem, Schamim H. Eckert, Mario Wurglics, Manfred Schubert‐Zsilavecz and Gunter P. Eckert

    Citation: Alzheimer's Research & Therapy 2018 10:18

    Content type: Research

    Published on:

  38. Alzheimer’s disease (AD) is a complex neurodegenerative disease, and genetic differences may mediate neuronal degeneration. In humans, a single-nucleotide polymorphism in the B-cell chronic lymphocytic leukemi...

    Authors: Chiung-Chih Chang, Ya-Ting Chang, Chi-Wei Huang, Shih-Jen Tsai, Shih-Wei Hsu, Shu-Hua Huang, Chen-Chang Lee, Wen-Neng Chang, Chun-Chung Lui and Chia-Yi Lien

    Citation: Alzheimer's Research & Therapy 2018 10:17

    Content type: Research

    Published on:

  39. Animal models of Alzheimer’s disease (AD) are essential to understanding the disease progression and to development of early biomarkers. Because AD has been described as a disconnection syndrome, magnetic reso...

    Authors: Emma Muñoz-Moreno, Raúl Tudela, Xavier López-Gil and Guadalupe Soria

    Citation: Alzheimer's Research & Therapy 2018 10:16

    Content type: Research

    Published on:

  40. Deep phenotyping and longitudinal assessment of predementia at-risk states of Alzheimer’s disease (AD) are required to define populations and outcomes for dementia prevention trials. Subjective cognitive decli...

    Authors: Frank Jessen, Annika Spottke, Henning Boecker, Frederic Brosseron, Katharina Buerger, Cihan Catak, Klaus Fliessbach, Christiana Franke, Manuel Fuentes, Michael T. Heneka, Daniel Janowitz, Ingo Kilimann, Christoph Laske, Felix Menne, Peter Nestor, Oliver Peters…

    Citation: Alzheimer's Research & Therapy 2018 10:15

    Content type: Research

    Published on:

  41. Despite a tremendous amount of information on the role of amyloid in Alzheimer’s disease (AD), almost all clinical trials testing this hypothesis have failed to generate clinically relevant cognitive effects.

    Authors: Hugo Geerts, Athan Spiros and Patrick Roberts

    Citation: Alzheimer's Research & Therapy 2018 10:14

    Content type: Research

    Published on:

  42. Accumulating evidence indicates that Tau pathology can spread from neuron to neuron by intake and coaggregation of the hyperphosphorylated Tau (p-Tau) seeds with the host neuron protein. Thus, clearance of Tau...

    Authors: Chun-ling Dai, Wen Hu, Yunn Chyn Tung, Fei Liu, Cheng-Xin Gong and Khalid Iqbal

    Citation: Alzheimer's Research & Therapy 2018 10:13

    Content type: Research

    Published on:

  43. Immunotherapy targeting the amyloid-β (Aβ) peptide is a promising strategy for the treatment of Alzheimer’s disease (AD); however, none of the active or passive vaccines tested have been demonstrated to be eff...

    Authors: Ana-María Lacosta, María Pascual-Lucas, Pedro Pesini, Diego Casabona, Virginia Pérez-Grijalba, Iván Marcos-Campos, Leticia Sarasa, Jesus Canudas, Hassnae Badi, Inmaculada Monleón, Itziar San-José, Josep Munuera, Octavio Rodríguez-Gómez, Carla Abdelnour, Asunción Lafuente, Mar Buendía…

    Citation: Alzheimer's Research & Therapy 2018 10:12

    Content type: Research

    Published on:

  44. Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by deposition of amyloid plaques and disruption of neural circuitry, leading to cognitive decline. Animal models of AD deposit senile plaq...

    Authors: Guillaume J. Pagnier, Ksenia V. Kastanenka, Miwon Sohn, Sangzin Choi, Song-hyen Choi, HyeYeon Soh and Brian J. Bacskai

    Citation: Alzheimer's Research & Therapy 2018 10:11

    Content type: Research

    Published on:

  45. Oligomeric forms of amyloid-β (Aβ) and tau are increasing being recognized as key toxins in the pathogenesis of Alzheimer’s disease (AD).

    Authors: Fernando Goñi, Mitchell Martá-Ariza, Krystal Herline, Daniel Peyser, Allal Boutajangout, Pankaj Mehta, Eleanor Drummond, Frances Prelli and Thomas Wisniewski

    Citation: Alzheimer's Research & Therapy 2018 10:10

    Content type: Research

    Published on:

  46. Kallikrein 6 (KLK6) is known to be an age-related protease expressed at high levels in the central nervous system. It was previously shown to be involved in proteolysis of extracellular proteins implicated in ...

    Authors: Kalicharan Patra, Antoninus Soosaipillai, Sigrid Botne Sando, Camilla Lauridsen, Guro Berge, Ina Møller, Gøril Rolfseng Grøntvedt, Geir Bråthen, Ilijana Begcevic, Simon Moussaud, Lennart Minthon, Oskar Hansson, Eleftherios P. Diamandis, Linda R. White and Henrietta M. Nielsen

    Citation: Alzheimer's Research & Therapy 2018 10:9

    Content type: Research

    Published on:

  47. Cerebrospinal fluid (CSF) neurofilament light (NfL) is a reliable marker of neuro-axonal damage in different neurological disorders that is related to disease severity. To date, all recent studies performed in...

    Authors: Lorenzo Gaetani, Kina Höglund, Lucilla Parnetti, Fani Pujol-Calderon, Bruno Becker, Paolo Eusebi, Paola Sarchielli, Paolo Calabresi, Massimiliano Di Filippo, Henrik Zetterberg and Kaj Blennow

    Citation: Alzheimer's Research & Therapy 2018 10:8

    Content type: Research

    Published on:

  48. In this paper, we describe the clinical and neuropathological findings of nine members of the Belgian progranulin gene (GRN) founder family. In this family, the loss-of-function mutation IVS1 + 5G > C was identif...

    Authors: Anne Sieben, Sara Van Mossevelde, Eline Wauters, Sebastiaan Engelborghs, Julie van der Zee, Tim Van Langenhove, Patrick Santens, Marleen Praet, Paul Boon, Marijke Miatton, Sofie Van Hoecke, Mathieu Vandenbulcke, Rik Vandenberghe, Patrick Cras, Marc Cruts, Peter Paul De Deyn…

    Citation: Alzheimer's Research & Therapy 2018 10:7

    Content type: Research

    Published on:

  49. Cognitive screeners are imperative for early diagnosis of dementia. The Visual Cognitive Assessment Test (VCAT) is a language-neutral, visual-based test which has proven useful for a multilingual population in...

    Authors: Levinia Lim, Tze Pin Ng, Anam Paulus Ong, Maw Pin Tan, Alvin Rae Cenina, Qi Gao, Adeline Ng and Nagaendran Kandiah

    Citation: Alzheimer's Research & Therapy 2018 10:6

    Content type: Research

    Published on:

  50. Given the complex and progressive nature of Alzheimer’s disease (AD), a precision medicine approach for diagnosis and treatment requires the identification of patient subgroups with biomedically distinct and a...

    Authors: Nophar Geifman, Richard E. Kennedy, Lon S. Schneider, Iain Buchan and Roberta Diaz Brinton

    Citation: Alzheimer's Research & Therapy 2018 10:4

    Content type: Research

    Published on:

Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Advertisement

Alzheimer's Research & Therapy

ISSN: 1758-9193